Phage-Antibiotic Synergy: definition, evaluation & prediction

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14310%2F24%3A00139972" target="_blank" >RIV/00216224:14310/24:00139972 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Phage-Antibiotic Synergy: definition, evaluation & prediction

Popis výsledku v původním jazyce

Phage – Antibiotic Synergy (PAS) is a phenomenon known for more than a decade. Basically, it means that the addition of a second antimicrobial agent should lead to a more effective eradication of the bacterial population. Unfortunately, the observation of PAS described in the literature varies in its signs. For example, as a result of a PAS effect, we could see an increase in the size of phage plaques. Another sign is an increase in the phage burst size or the sooner onset of the phage lysis. Usually, lots of these studies lack a full overview of all the signs of synergy for a combination tested, where the synergy was declared. Another weakness is the lack of a common framework for the evaluation of phage-antibiotic interactions. All these factors contribute to the incomparability of gained results and slow down the overall knowledge in the field. For all these reasons, we decided to evaluate PAS in a set of 24 S. aureus strains comprising 21 clinical strains, 12 of which were MRSA.

Název v anglickém jazyce

Phage-Antibiotic Synergy: definition, evaluation & prediction

Popis výsledku anglicky

Phage – Antibiotic Synergy (PAS) is a phenomenon known for more than a decade. Basically, it means that the addition of a second antimicrobial agent should lead to a more effective eradication of the bacterial population. Unfortunately, the observation of PAS described in the literature varies in its signs. For example, as a result of a PAS effect, we could see an increase in the size of phage plaques. Another sign is an increase in the phage burst size or the sooner onset of the phage lysis. Usually, lots of these studies lack a full overview of all the signs of synergy for a combination tested, where the synergy was declared. Another weakness is the lack of a common framework for the evaluation of phage-antibiotic interactions. All these factors contribute to the incomparability of gained results and slow down the overall knowledge in the field. For all these reasons, we decided to evaluate PAS in a set of 24 S. aureus strains comprising 21 clinical strains, 12 of which were MRSA.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

10606 - Microbiology

Projekt

<a href="/cs/project/NU21J-05-00035" target="_blank" >NU21J-05-00035: Synergie lytických bakteriofágů a antibiotik v léčbě povrchových infekcí způsobených Staphylococcus aureus</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2024

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů